Another New Home For Momelotinib As GSK Buys Sierra
Drug Major Pays $1.9bn To Boost Blood Cancer Pipeline
GlaxoSmithKline is paying a 39% premium to buy Sierra Oncology and its myelofibrosis therapy momelotinib which is set to be filed shortly in the US on the back of a strong Phase III package.
